Investigation Into Sage Therapeutics
Recent news about Sage Therapeutics, Inc. (NASDAQ: SAGE) has sparked an investigation led by law firms representing investors who may have been affected. This comes amid mounting scrutiny over substantial declines in the company’s stock price, which are tied to announcements about its drug applications and study outcomes.
Effects of FDA Approvals
In a notable update, Sage Therapeutics announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for zuranolone, specifically for treating postpartum depression (PPD). However, the FDA also issued a Complete Response Letter (CRL) concerning the application for major depressive disorder (MDD), pointing out that there wasn’t enough evidence to demonstrate effectiveness. As a result, the stock took a sharp dive, falling $19.35— a staggering 53.6%— with shares closing at $16.75 right after the announcement.
Effects of Clinical Study Findings
The trouble continued on April 17, 2024, when Sage released disappointing results from a Phase 2 study of SAGE-718, which was intended to treat mild cognitive impairment related to Parkinson's disease. The study did not meet its primary endpoint, showing no meaningful differences between the treated group and the placebo. Consequently, Sage decided to terminate any further development of SAGE-718, leading to another significant decline in its stock, which dropped by $3.06, or 19.6%, finishing at $12.57.
Additional Complications with Sage-324
As if things couldn't get any worse, on July 24, 2024, Sage shared outcomes from a Phase 2 study of SAGE-324 focused on essential tremor. The results showed no significant dose-response relationships, prompting Sage to halt ongoing studies and consider stopping further development. The market reacted quickly, with Sage's stock price falling by $2.70, or 20.6%, landing at $10.38 per share.
Support for Investors
These troubling announcements have raised significant concerns among investors regarding their rights and interests. For those who have purchased Sage securities and are looking to explore their legal options, reaching out to the Law Offices of Howard G. Smith is recommended. Howard G. Smith, Esquire, can assist with inquiries pertaining to these recent developments.
Conclusion and Contact Details
The Law Offices of Howard G. Smith are dedicated to helping investors who might be affected by these critical setbacks. Investors are encouraged to contact the office directly for more information about their rights or any questions regarding the current situation. The law office is located at 3070 Bristol Pike, Suite 112, and can be reached directly at (215) 638-4847.
Frequently Asked Questions
What led to the investigation into Sage Therapeutics?
The investigation began due to significant drops in the company’s stock price following their announcements regarding FDA approvals and clinical study outcomes.
What were the results of the FDA's response to Sage's drug applications?
The FDA's issuance of a Complete Response Letter for zuranolone's application targeting MDD caused a notable decrease in the company’s stock price.
How did the Phase 2 study results impact Sage's stock?
Disappointing results from the Phase 2 studies of SAGE-718 and SAGE-324 led to major declines in Sage's stock price, which diminished investor confidence.
What should investors do if they have concerns about Sage Therapeutics?
Investors who are worried about their investments in Sage Therapeutics should contact the Law Offices of Howard G. Smith for advice and to discuss possible legal options.
How can I find more information about the investigation?
Investors can call the Law Offices of Howard G. Smith directly for further details about the investigation and any related questions.
